Bristol Myers Squibb (BMS) is an American multinational pharmaceutical company, headquartered in New York City. Bristol Myers Squibb manufactures prescription pharmaceuticals and biologics in several therapeutic areas, including cancer, AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders.
| Revenue (TTM) | $49.19B |
| Gross Profit (TTM) | $35.25B |
| EBITDA | $18.93B |
| Operating Margin | 34.40% |
| Return on Equity | 46.60% |
| Return on Assets | 10.70% |
| Revenue/Share (TTM) | $24.14 |
| Book Value | $10.93 |
| Price-to-Book | 5.60 |
| Price-to-Sales (TTM) | 2.61 |
| EV/Revenue | 3.231 |
| EV/EBITDA | 9.45 |
| Quarterly Earnings Growth (YoY) | 153.10% |
| Quarterly Revenue Growth (YoY) | 5.70% |
| Shares Outstanding | $2.04B |
| Float | $2.04B |
| % Insiders | 0.10% |
| % Institutions | 84.87% |
Volatility is currently contracting
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #IMS26--BMS Announces First Presentation of Results for ZENBEXUS™ (iberdomide) in Combination with Daratumumab from Phase 3 EXCALIBER-RRMM Trial.
BMY, HALO, TGT, NEO and ROST stocks show how women-led companies are redefining growth with discipline, agility and results.
Bristol Myers Squibbs' growth portfolio is gaining ground, with newer drugs offsetting mature-product declines and reshaping its revenue mix.
BMY, HRTG, RDVT, NMR and ECO have been added to the Zacks Rank #1 (Strong Buy) List on September 24th, 2026.
ECO, NMR, BMY made it to the Zacks Rank #1 (Strong Buy) income stocks list on September 24th, 2026.
Patent cliffs have buried lesser pharma dividends, yet these four Big Pharma giants keep raising payouts despite losing blockbuster exclusivities worth billions.
Bristol Myers' growth portfolio and pipeline advances offer multiple ways to offset legacy-product erosion, while valuation and leverage remain key factors.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Bristol Myers' Sotyktu delivers durable PsA responses for two years, supporting its growth strategy as competition intensifies.
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Bristol Myers Squibb (BMY) and argenex SE (ARGX). But which of these two stocks presents investors with the better value opportunity right now?
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on BMY and any ticker you trade — then tracks every position and per-strategy win rate.
